Business
InMed Pharmaceuticals Strengthens Patent Portfolio with Issuance of Three U.S. Patents
InMed's intellectual property portfolio totals 13 patent families covering new chemical entities, formulations, manufacturing methods and methods of use
About this update from Inmed Pharmaceuticals Inc.
[{"type":"text","content":"\nInMed's intellectual property portfolio totals 13 patent families covering new chemical entities, formulations, manufacturing methods and methods of use\n\nVancouver, British Columbia--(Newsfile Corp. - August 21, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) (\"InMed\" or the \"Company\"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced it has been issued three U.S. patents: one for its formulation and method of use in the treatment of epidermolysis bullosa and related connective tissue disorders, one for biosynthesis manufacturing processes and one for an ocular drug delivery formulation.\nThe method of use patent, entitled \"Use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders\" relates to INM-755 drug candidate which has completed a Phase 2 clinical trial in the treatment of symptoms related to epidermolysis bullosa. The patent has now been granted in the U.S., Australia, Japan and Israel and is pending in several other jurisdictions. The biosynthesis patent for the manufacturing of proprietary analogs for our drug development programs has been granted in U.S. Additionally, an ocular drug delivery formulation and use patent has been granted/allowed in the U.S., Europe, Australia, Japan, and India and is also pending in other jurisdictions.\nAs of August 20, 2024, InMed has a total of 13 patent families covering new chemical entities, formulations, manufacturing processes and methods of use. The Company continues to pursue new chemical entity patents on the drug candidates for both its INM-901 program in Alzheimer's disease and INM-089 in dry Age-related Macular Degeneration.\nSummary of Granted Patents (to date):\n\n\n\nSubject Matter\nScope\nStatus and jurisdiction\n\n\nUse of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders\nMethod of Use\nGranted: US, Australia, Japan, Israel\nPending: Several jurisdictions\n\n\nMetabolic engineering of E. coli for the biosynthesis of cannabinoid products\nManufacturing Process\nGranted: U.S. (will be issued on 9/3/24)\nPending: Several jurisdictions\n\n\nOcular drug delivery formulation\nFormulation, Method of Use\nGranted/Allow...